Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharmosa BiopharmROCO:6875 +0.42%11 PS Ratio is 68.68 as of Jul. 23, 2026, which is 78% above its 10-year median of 38.66. GuruFocus rates ROCO:6875 with a GF Score™ of 11/100. The stock has 1 warning sign investors should review. Among 930 Biotechnology companies, Pharmosa Biopharm ranks worse than 81.83% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Pharmosa Biopharm's share price is NT$35.85.
Pharmosa Biopharm's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was NT$0.52. Hence, Pharmosa Biopharm's PS Ratio for today is 68.68.
The historical rank and industry rank for Pharmosa Biopharm's PS Ratio or its related term are showing as below:
ROCO:6875'
s PS Ratio Range Over the Past 10 Years
Min: 18.3 Med: 38.66 Max: 181.38
Current: 68.68
During the past 8 years, Pharmosa Biopharm's highest PS Ratio was 181.38. The lowest was 18.30. And the median was 38.66.
ROCO:6875's PS Ratio is ranked worse than 81.83% of 930
companies
in the Biotechnology industry
Industry Median: 9.205
vs ROCO:6875: 68.68
Pharmosa Biopharm (ROCO:6875) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Pharmosa Biopharm PS Ratio Related Terms
Pharmosa Biopharm PS Ratio Historical Data
* Premium members only.
The historical data trend for Pharmosa Biopharm's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6875 vs VRTX, REGN, ALNY: PS Ratio Comparison
For the Biotechnology subindustry, Pharmosa Biopharm's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharmosa Biopharm PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharmosa Biopharm's PS Ratio distribution charts can be found below:
* The bar in red indicates where Pharmosa Biopharm's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Pharmosa Biopharm's Share Price of today is NT$35.85. Pharmosa Biopharm's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$0.52.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Pharmosa Biopharm (ROCO:6875) has a PS Ratio of 68.68 as of Jul. 23, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Pharmosa Biopharm and its competitors. This is 78% above median its historical median of 38.66. Over the past decade, Pharmosa Biopharm's PS Ratio has ranged from 18.30 to 181.38. According to the industry distribution chart, Pharmosa Biopharm ranks #761 out of 930 companies in the Biotechnology industry, placing it in the top 81.8%.
Is Pharmosa Biopharm's PS Ratio too high?
Pharmosa Biopharm's current PS Ratio of 68.68 is 78% above median its 10-year median of 38.66. Over the past 10 years, this metric has ranged from a low of 18.30 to a high of 181.38. The Biotechnology industry median PS Ratio is 9.21. Pharmosa Biopharm's value of 68.68 is 646.1% above this industry median. Based on the distribution chart, Pharmosa Biopharm ranks #761 out of 930 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Pharmosa Biopharm has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Pharmosa Biopharm's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharmosa Biopharm ranks #761 out of 930 companies for PS Ratio. This places Pharmosa Biopharm in the lower half of its industry. The industry median PS Ratio is 9.21. Pharmosa Biopharm's value of 68.68 is 646.1% above this benchmark. Historically, Pharmosa Biopharm's own PS Ratio has ranged from 18.30 to 181.38 over the past decade. While the company's 10-year median is 38.66 vs. the industry median of 9.21, Pharmosa Biopharm has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.21, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharmosa Biopharm's current PS Ratio of 68.68 is 646.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Pharmosa Biopharm and its competitors. For the Biotechnology industry, the median PS Ratio is 9.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharmosa Biopharm's current PS Ratio is 68.68, which is 78% above median its own 10-year median of 38.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmosa Biopharm stock overvalued right now?
Pharmosa Biopharm (ROCO:6875) has a current PS Ratio of 68.68. The current PS Ratio is 68.68, which is 78% above median its 10-year median of 38.66 and 646.1% above the Biotechnology industry median of 9.21. Pharmosa Biopharm's overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Pharmosa Biopharm (ROCO:6875), the current PS Ratio is 68.68 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pharmosa Biopharm Inc is a world-class biotechnology company. The Company's principal business activities comprise the development and commercialization of inventive biopharmaceutical drugs. Its product portfolio includes sustained-release dosage forms and drug-device combination products intended for home based therapies.
11GF Score
Get the complete analysis for ROCO:6875
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6875 has been successfully added to your 
